Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Prelude Therapeutics Inc changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of PRLD: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders5950−9
Shares30.5M27.2M−3.35M (−11.0%)
Value$23.3M$22.0M−$1.32M (−5.6%)

New holders (8)

Institutions that held Prelude Therapeutics Inc at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to PRLD in Q2 2025
InstitutionSharesValue% of portfolio
Cantor Fitzgerald, L. P.211,859$171.5K0.00%
Jane Street Group, LLC91,753$74.3K0.00%
Shay Capital LLC75,000$60.7K0.01%
Gsa Capital Partners LLP71,378$58.0K0.00%
Y-Intercept (Hong Kong) Ltd47,788$38.7K0.00%
Marshall Wace, LLP41,747$33.8K0.00%
Essential Partners LLC87$700.00%
IFP Advisors, Inc34$280.00%

Sold out (17)

Institutions that held Prelude Therapeutics Inc at the end of Q1 2025 and filed for Q2 2025 without it.